keyword
MENU ▼
Read by QxMD icon Read
search

infliximab level

keyword
https://www.readbyqxmd.com/read/27931515/autologous-adipose-derived-mesenchymal-stromal-cells-for-the-treatment-of-psoriasis-vulgaris-and-psoriatic-arthritis-a-case-report
#1
Miguel M De Jesus, Jayson S Santiago, Camille V Trinidad, Melvin E See, Kimberly R Semon, Manuel O Fernandez, Francisco S Chung
Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Declaration of Helsinki. The protocol was approved by the Cellular Transplantation Ethics Committee of the Makati Medical Center. Autologous MSCs were cultured from lipoaspirate and expanded in a clean room class 100 facility (Cellular Therapeutics Center, Makati Medical Center)...
November 2016: Cell Transplantation
https://www.readbyqxmd.com/read/27930804/increased-mitochondrial-ros-generation-mediates-the-loss-of-pvat-anticontractile-effect-in-hfd-treated-obese-mice
#2
Rafael Menezes da Costa, Rafael S Fais, Carlos R P Dechandt, Paulo Louzada-Junior, Luciane C Alberici, Núbia S Lobato, Rita C Tostes
Obesity is associated with structural and functional changes in the perivascular adipose tissue (PVAT), favoring the release of reactive oxygen species (ROS), vasoconstrictor and proinflammatory factors. Tumor necrosis factor alpha (TNF-α) induces vascular dysfunction and is produced by the PVAT. We tested the hypothesis that obesity-associated PVAT dysfunction is mediated by augmented mitochondrial ROS (mROS) generation due to increased TNF-α production in this tissue. Aortae from high fat diet (HFD)-fed obese mice displayed increased contractions to phenylephrine (PE) and loss of PVAT anticontractile effect...
December 8, 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/27909436/evaluation-of-anti-inflammatory-effects-of-steroids-and-arthritis-related-biotherapies-in-an-in-vitro-coculture-model-with-immune-cells-and-synoviocytes
#3
Mélissa Noack, Ndiémé Ndongo-Thiam, Pierre Miossec
BACKGROUND: During rheumatoid arthritis (RA), steroids and biotherapies are used alone and combined. Efficacy has been established in clinical trials but their differential effects at the cellular level are less documented. The aim was to study these cellular effects using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in the RA synovium. METHODS: Activated-PBMC were cocultured with RA synoviocytes during 48 h...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27904147/penile-constitutive-nitric-oxide-synthase-expression-in-rats-exposed-to-unpredictable-chronic-mild-stress-role-of-inflammation
#4
T D Şahin, Y Yazır, T Utkan, S S Göçmez, D Bayramgürler
Chronic psychological stress cause erectile dysfunction (ED). Considering recent evidence that tumor necrosis factor-α (TNF-α) levels are increased in serum of patients with ED, the present study investigated the effects of infliximab (a TNF-α blocker) on endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) immunoreactivity of rat penile corpus cavernosum in unpredictable chronic mild stress (UCMS). Male adult rats were randomly divided into three groups (n=8 per group): Control, UCMS and UCMS+infliximab...
December 1, 2016: International Journal of Impotence Research
https://www.readbyqxmd.com/read/27882586/efficacy-and-safety-of-dose-escalation-of-infliximab-therapy-in-japanese-patients-with-psoriasis-results-of-the-spread-study
#5
Hideshi Torii, Masayuki Nakano, Toshiro Yano, Kazuoki Kondo, Hidemi Nakagawa
Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard-dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard-dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75...
November 24, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27862102/addition-of-an-immunomodulator-can-reverse-antibody-formation-and-loss-of-response-in-patients-treated-with-adalimumab
#6
B Ungar, U Kopylov, T Engel, M Yavzori, E Fudim, O Picard, A Lang, N Williet, S Paul, Y Chowers, A Bar-Gil Shitrit, R Eliakim, S Ben-Horin, X Roblin
BACKGROUND: Anti-adalimumab antibodies (AAA) are associated with loss of clinical response (LOR). Addition of an immunomodulator has been shown to reverse immunogenicity and regain response with infliximab monotherapy. Similar data on adalimumab are lacking. AIM: To study the impact of immunomodulator addition on the emergence of AAA and LOR among adalimumab therapy patients. METHODS: The databases of three tertiary medical centres were reviewed to identify patients who developed AAA during adalimumab monotherapy with resultant LOR, and received an immunomodulator as a salvage combination therapy...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27853420/reducing-peripheral-inflammation-with-infliximab-reduces-neuroinflammation-and-improves-cognition-in-rats-with-hepatic-encephalopathy
#7
Sherry Dadsetan, Tiziano Balzano, Jerónimo Forteza, Andrea Cabrera-Pastor, Lucas Taoro-Gonzalez, Vicente Hernandez-Rabaza, Sara Gil-Perotín, Laura Cubas-Núñez, José-Manuel García-Verdugo, Ana Agusti, Marta Llansola, Vicente Felipo
Inflammation contributes to cognitive impairment in patients with hepatic encephalopathy (HE). However, the process by which peripheral inflammation results in cognitive impairment remains unclear. In animal models, neuroinflammation and altered neurotransmission mediate cognitive impairment. Taking into account these data, we hypothesized that in rats with HE: (1) peripheral inflammation is a main contributor to neuroinflammation; (2) neuroinflammation in hippocampus impairs spatial learning by altering AMPA and/or NMDA receptors membrane expression; (3) reducing peripheral inflammation with infliximab (anti-TNF-a) would improve spatial learning; (4) this would be associated with reduced neuroinflammation and normalization of the membrane expression of glutamate receptors...
2016: Frontiers in Molecular Neuroscience
https://www.readbyqxmd.com/read/27845027/clinical-effectiveness-and-cost-effectiveness-of-use-of-therapeutic-monitoring-of-tumour-necrosis-factor-alpha-tnf-%C3%AE-inhibitors-lisa-tracker%C3%A2-enzyme-linked-immunosorbent-assay-elisa-kits-tnf-%C3%AE-blocker-elisa-kits-and-promonitor%C3%A2-elisa-kits-versus-standard-care
#8
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
BACKGROUND AND OBJECTIVES: Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using LISA-TRACKER(®) enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor(®) ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn's disease (CD)...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27832688/changes-in-body-mass-index-and-lipid-profile-in-psoriatic-patients-after-treatment-with-standard-protocol-of-infliximab
#9
Amir Houshang Ehsani, Hossein Mortazavi, Kamran Balighi, Mahboubeh Sadat Hosseini, Arghavan Azizpour, Seyyedeh Pardis Hejazi, Azadeh Goodarzi, Seyyedeh Bahareh Darvari
Psoriasis is a chronic and inflammatory dermatologic disease. Psoriasis may predispose to cardiovascular disease and diabetes. However, the role of tumor necrosis factor (TNF) inhibitor in mediating this risk is controversial. Regarding frequent use of infliximab in psoriasis, and the hypothesis that anti TNF-α treatment may increase Body Mass Index (BMI) and alter lipid profile in these patients, the aim of this study was to assess changes in BMI and Lipid Profile and level of leptin in Psoriatic Patients under Treatment of Standard Protocol of Infliximab in a 24 week period...
September 2016: Acta Medica Iranica
https://www.readbyqxmd.com/read/27824651/infliximab-selectively-modulates-the-circulating-blood-monocyte-repertoire-in-crohn-s-disease
#10
Stephanie M Slevin, Michael Conall Dennedy, Eanna P Connaughton, Andreia Ribeiro, Rhodri Ceredig, Matthew D Griffin, Laurence J Egan
BACKGROUND: Infliximab (IFX), an anti-tumour necrosis factor alpha (TNFα) monoclonal antibody, provides clinical benefits in treating Crohn's disease (CD) but its mechanisms of action are not fully elucidated. This study investigated blood monocyte repertoires and the acute effects of IFX infusion on monocyte subset phenotype and function in IFX-treated patients with CD. METHODS: Monocytes and monocyte subsets were enumerated and phenotypically characterized by multicolor flow cytometry in freshly isolated blood from healthy controls (n = 21) and patients with CD treated with (IFX, n = 24) and without (non-IFX, n = 20) IFX...
December 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27821943/green-tea-and-exercise-interventions-as-nondrug-remedies-in-geriatric-patients-with-rheumatoid-arthritis
#11
Ahmad H Alghadir, Sami A Gabr, Einas S Al-Eisa
This study aimed to evaluate the effects of green tea and supervised exercise training interventions on improvement of disease activity and bone metabolism markers in rheumatoid arthritis patients. [Subjects and Methods] One-hundred and twenty subjects who had a mean age of (60.7 ± 2.53 years) and had been diagnosed with rheumatoid arthritis at least ten years previously were randomly included in this study. Patients were treated with infliximab, green tea, or a supervised exercise program for six months...
October 2016: Journal of Physical Therapy Science
https://www.readbyqxmd.com/read/27808043/optimizing-biological-treatment-in-rheumatoid-arthritis-with-the-aid-of-therapeutic-drug-monitoring
#12
Grith Petersen Eng
The treatment of rheumatoid arthritis (RA) has greatly improved with the use of biological TNF inhibitors (TNFi). These biopharmaceuticals target the inflammatory cytokine TNF, and hereby decrease the autoimmune inflammation, which may otherwise lead to permanent joint damage in the afflicted patients. Although TNFi decrease clinical disease activity in the majority of the treated patients, they are not always effective. Some patients have a partial response, some lose their initial response to treatment, and others never experience effect at all...
November 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27806720/kawasaki-disease-in-sicily-clinical-description-and-markers-of-disease-severity
#13
Maria Cristina Maggio, Giovanni Corsello, Eugenia Prinzi, Rolando Cimaz
BACKGROUND: Kawasaki disease (KD) is an acute systemic vasculitis of small and middle size arteries; 15-25 % of untreated patients and 5 % of patients treated with intravenous immunoglobulin (IVIG) develop coronary artery lesions (CAL). Many studies tried to find the most effective treatment in the management of resistant KD and to select the risk factors for CAL. Our data are assessed on children from west Sicily, characterized by a genetic heterogeneity. METHODS: We studied the clinical data of 70 KD Sicilian children (36 males: 51 %; 34 females: 49 %), analysed retrospectively, including: demographic and laboratory parameters; echocardiographic findings at diagnosis, at 2, 6 and 8 weeks, and at 1 year after the onset of the illness...
November 2, 2016: Italian Journal of Pediatrics
https://www.readbyqxmd.com/read/27803733/detection-of-anti-infliximab-antibodies-is-impacted-by-antibody-titer-infliximab-level-and-igg4-antibodies-a-systematic-comparison-of-three-different-assays
#14
Joana Afonso, Susana Lopes, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Ana Isabel Vieira, Rosa Coelho, Patrícia Tavares, João Soares, Ana Lúcia Sousa, Diana Carvalho, Paula Sousa, João Pereira da Silva, Tânia Meira, Filipa Silva Ferreira, Cláudia Camila Dias, Yehuda Chowers, Shomron Ben-Horin, Fernando Magro
BACKGROUND: There is scant information on the accuracy of different assays used to measure anti-infliximab antibodies (ADAs), especially in the presence of detectable infliximab (IFX). We thus aimed to evaluate and compare three different assays for the detection of IFX and ADAs and to clarify the impact of the presence of circulating IFX on the accuracy of the ADA assays. METHODS: Blood samples from 79 ulcerative colitis (UC) patients treated with infliximab were assessed for IFX levels and ADAs using three different assays: an in-house assay and two commercial kits, Immundiagnostik and Theradiag...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803139/physical-function-and-spinal-mobility-remain-stable-despite-radiographic-spinal-progression-in-patients-with-ankylosing-spondylitis-treated-with-tnf-%C3%AE-inhibitors-for-up-to-10-years
#15
Denis Poddubnyy, Aleksandra Fedorova, Joachim Listing, Hildrun Haibel, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper
OBJECTIVE: The aim of the study was to investigate the effect of radiographic spinal progression and disease activity on function and spinal mobility in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNF-α) inhibitors for up to 10 years. METHODS: Patients with AS who participated in 2 longterm open-label extensions of clinical trials with TNF-α inhibitors (43 receiving infliximab and 17 receiving etanercept) were included in this analysis based on the availability of spinal radiographs performed at baseline and at a later timepoint (yr 2, 4, 6, 8, and 10) during followup...
December 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27800198/a-case-report-of-neurosarcoidosis-presenting-as-a-lymphoma-mimic
#16
Gurcharanjeet Kaur, Lauren Cameron, Olga Syritsyna, Patricia Coyle, Agnes Kowalska
Objective. To describe a unique presentation of neurosarcoidosis. Background. Central nervous system involvement is rare in sarcoidosis. Sarcoidosis can be severe and can be mistaken for systemic lymphoma. Case Description. A 55-year-old right-handed white male with past medical history of obstructive sleep apnea, Raynaud's disease, and Hashimoto's thyroiditis was noted to have cognitive decline over a duration of few weeks and 20 lb weight loss. His neurologic exam (including cranial nerves) was normal except for five-minute recall...
2016: Case Reports in Neurological Medicine
https://www.readbyqxmd.com/read/27797269/concurrent-immunomodulator-therapy-is-associated-with-higher-adalimumab-trough-levels-during-scheduled-maintenance-therapy
#17
Ashley Bond, Susanna Dodd, Gareth Fisher, Thomas Skouras, Sreedhar Subramanian
INTRODUCTION: Combination therapy with infliximab and immunomodulators is superior to monotherapy, resulting in better outcomes and higher trough levels of infliximab. The role of concurrent immunomodulatory therapy on adalimumab trough levels has not been adequately investigated. We evaluated the impact of concomitant immunomodulation on adalimumab trough levels in patients on scheduled maintenance therapy. METHOD: We conducted a prospective observational, cross-sectional study of all inflammatory bowel disease patients on maintenance therapy who had adalimumab trough levels measured between January 2013 and January 2016...
October 31, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27781498/infliximab-therapy-reverses-the-increase-of-allograft-inflammatory-factor-1-in-serum-and-colonic-mucosa-of-rats-with-inflammatory-bowel-disease
#18
Irene D Román, David Cano-Martínez, María Val T Lobo, María Dolores Fernández-Moreno, Borja Hernández-Breijo, Silvia Sacristán, Patricia Sanmartín-Salinas, Jorge Monserrat, Javier P Gisbert, Luis G Guijarro
: Objetive: Our purpose was to study the molecular basis of infliximab (IFX) effect on colon mucosa in a colitis model and to identify new biomarkers of mucosal healing. METHODS: Healthy rats and rats which were subjected to experimental colitis induced by dextran sulphate sodium, with or without IFX treatment (in the short- and long-term), were studied along with forty-seven IBD patients. Colon mucosal integrity by Periodic Acid Schiff staining, intestinal damage by immunohistochemistry (proliferating cell nuclear antigen, β-catenin, E-cadherin, phosphotyrosine, p-p38, allograft inflammatory factor-1 (AIF-1) and colonic mucosal apoptosis by TUNEL staining were evaluated in rats...
October 26, 2016: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/27778459/infliximab-is-equivalently-suppressing-oxidative-stress-compared-to-tocilizumab-among-well-controlled-patients-with-rheumatoid-arthritis
#19
Kazuha Kizaki, Fumiharu Yamashita, Tomoya Hayashi, Noboru Funakoshi
AIM: This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-controlled patients with RA. METHODS: We recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with RA using biological agents (infliximab n = 33; tocilizumab n = 28), active RA patients with CRP > 1...
October 24, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/27762509/analytical-and-clinical-evaluation-of-an-immunoassay-for-estimating-immunogenicity-of-infliximab-and-etanercept-in-indian-population
#20
Canna Ghia, Shashank Akerkar, Shailaja Sabnis, Urk Rao, Gautam Rambhad
BACKGROUND / OBJECTIVES: Biologic anti-TNFs in India have improved the patient management. Significant proportions of patients lose response over time or do not respond. Possible explanations are suboptimal trough anti-TNFa concentrations or antibodies to anti-TNFs. The aim of this project was to set up and standardize an independent laboratory to test immunogenicity of anti-TNF biologics (infliximab and etanercept). METHODS: Three rheumatologists piloted this project approved by independent ethics committee and carried out in compliance with ICH/GCP guidelines...
September 2016: Journal of the Association of Physicians of India
keyword
keyword
53792
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"